Renal Thrombotic Microangiopathy in Proliferative Lupus Nephritis: Risk Factors and Clinical Outcomes: A Case-Control Study

Journal of Clinical Rheumatology

Volumn 22, Issue 5, 2016, Pages 235-240

  Barrera Vargas, Ana ^a   Rosado Canto, Rodrigo ^a   Merayo Chalico, Javier ^a   Arreola Guerra, José M ^b   Mejía Vilet, Juan M ^a   Correa Rotter, Ricardo ^a   Gómez Martín, Diana ^a   Alcocer Varela, Jorge ^a,b  

^a Department of Immunology and Rheumatology ^*  (United States)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

lupus nephritis; lymphopenia; systemic lupus erythematosus; thrombotic microangiopathies

Indexed keywords

PREDNISONE; RO ANTIBODY; ANTIRHEUMATIC AGENT; PHOSPHOLIPID ANTIBODY;

ADULT; ARTICLE; CAPILLARY PROLIFERATION; CASE CONTROL STUDY; CHRONICITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTOPENIA; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENAL THROMBOTIC MICROANGIOPATHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME; BIOPSY; HEMODIALYSIS; KIDNEY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; LYMPHOCYTE COUNT; MEXICO; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT ACUITY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIRHEUMATIC AGENTS; BIOPSY; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; LYMPHOCYTE COUNT; MALE; MEXICO; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT ACUITY; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; THROMBOTIC MICROANGIOPATHIES;

EID: 84982915216     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000425     Document Type: Article

References (47)

1. Borchers AT Leibushor N Naguwa SM Lupus nephritis: a critical review. Autoimmun Rev. 2012; 12: 174-194.
2. Weening JJ D'Agati VD Schwartz MM The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004; 65: 521-530.
3. Wu LH Yu F Tan Y Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013; 83: 715-723.
4. Appel GB Pirani CL D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol. 1994; 4: 1499-1515.
5. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347: 589-600.
6. Copelovitch L Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol. 2008; 23: 1761-1767.
7. Banfi G Bertani T Boeri V Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis. 1991; 18: 240-248.
8. Barber C Herzenberg A Aghdassi E Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol. 2012; 7: 757-764.
9. Tsumagari T Fukumoto S Kinjo M Incidence and significance of intrarenal vasculopathies in patients with systemic lupus erythematosus. Hum Pathol. 1985; 16: 43-49.
10. Descombes E Droz D Drouet L Renal vascular lesions in lupus nephritis. Medicine. 1997; 76: 355-368.
11. Song D Wu LH Wang FM The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther. 2013; 15: R12.
12. Shah AA Higgins JP Chakravarty EF. Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties. Nat Clin Pract Rheumatol. 2007; 3: 357-362.
13. Hu WX Liu ZZ Chen HP Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus. 2010; 19: 1591-1598.
14. Bridoux F Vrtovsnik F Noel C Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival. Nephrol Dialysis Transplant. 1998; 13: 298-304.
15. Chen MH Chen MH Chen WS Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology. 2011; 50: 768-775.
16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
17. Levey AS Stevens LA Schmid CH A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604-612.
18. Gladman DD Ibanez D Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002; 29: 288-291.
19. Veyradier A Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost. 2005; 3: 2420-2427.
20. Coppo P Veyradier A. Thrombotic microangiopathies: towards a pathophysiology-based classification. Cardiovasc Hematol Disord Drug Targets. 2009; 9: 36-50.
21. Cohen D Koopmans M Kremer Hovinga IC Potential for glomerular C4d as an indicator of thrombotic microangiopathy in lupus nephritis. Arthritis Rheum. 2008; 58: 2460-2469.
22. Lee PY Li Y Richards HB Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007; 56: 3759-3769.
23. Carmona-Rivera C Zhao W Yalavarthi S Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis. 2014.
24. Villanueva E Yalavarthi S Berthier CC Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011; 187: 538-552.
25. Constans J Dupuy R Blann AD Anti-endothelial cell autoantibodies and soluble markers of endothelial cell dysfunction in systemic lupus erythematosus. J Rheumatol. 2003; 30: 1963-1966.
26. Grisar J Steiner CW Bonelli M Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology. 2008; 47: 1476-1483.
27. Castejon R Jimenez-Ortiz C Valero-Gonzalez S Decreased circulating endothelial progenitor cells as an early risk factor of subclinical atherosclerosis in systemic lupus erythematosus. Rheumatology. 2014; 53: 631-638.
28. Vila LM Alarcon GS McGwin G Jr Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum. 2006; 55: 799-806.
29. Mirzayan MJ Schmidt RE Witte T. Prognostic parameters for flare in systemic lupus erythematosus. Rheumatology. 2000; 39: 1316-1319.
30. Drenkard C Villa AR Reyes E Vasculitis in systemic lupus erythematosus. Lupus. 1997; 6: 235-242.
31. Yu HH Wang LC Lee JH Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients. Rheumatology. 2007; 46: 1492-1494.
32. Huang YL Chung HT Chang CJ Lymphopenia is a risk factor in the progression of carotid intima-media thickness in juvenile-onset systemic lupus erythematosus. Arthritis Rheum. 2009; 60: 3766-3775.
33. Dhir V Singh AP Aggarwal A Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study. Lupus. 2009; 18: 785-791.
34. Bohm I. Apoptosis: the link between autoantibodies and leuko-/lymphocytopenia in patients with lupus erythematosus. Scand J Rheumatol. 2004; 33: 409-416.
35. Fan H Liu F Dong G Activation-induced necroptosis contributes to B-cell lymphopenia in active systemic lupus erythematosus. Cell death & disease. 2014; 5: e1416.
36. Gaipl US Voll RE Sheriff A Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev. 2005; 4: 189-194.
37. Merayo-Chalico J Demichelis-Gomez R Rajme-Lopez S Risk factors and clinical profile of thrombotic thrombocytopenic purpura in systemic lupus erythematosus patients. Is this a distinctive clinical entity in the thrombotic microangiopathy spectrum?: A case control study. Thromb Res. 2014; 134: 1020-1027.
38. Vaudo G Bocci EB Shoenfeld Y Precocious intima-media thickening in patients with primary Sjogren's syndrome. Arthritis Rheum. 2005; 52: 3890-3897.
39. Pons-Estel GJ Cervera R. Renal involvement in antiphospholipid syndrome. Curr Rheumatol Rep. 2014; 16: 397.
40. Sciascia S Cuadrado MJ Khamashta M Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol. 2014; 10: 279-289.
41. Tektonidou MG Sotsiou F Nakopoulou L Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004; 50: 2569-2579.
42. Silvarino R Sant F Espinosa G Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus. Lupus. 2011; 20: 721-729.
43. Bao L Haas M Quigg RJ. Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol. 2011; 22: 285-295.
44. Scully M Hunt BJ Benjamin S Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158: 323-335.
45. Contreras G Lenz O Pardo V Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 2006; 69: 1846-1851.
46. Seligman VA Lum RF Olson JL Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med. 2002; 112: 726-729.
47. Barr RG Seliger S Appel GB Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003; 18: 2039-2046.